Hanae Kondo
Papers
1
Total Citations
5
H-Index
1
About
Dr. Hanae Kondo is a pioneering oncologic surgeon whose work centers on the surgical management of advanced renal cell carcinoma (RCC), particularly cases complicated by inferior vena cava (IVC) tumor thrombus. Her most cited research, published in 2024, represents a landmark contribution to the field by demonstrating the feasibility and safety of combining preoperative lenvatinib and pembrolizumab—a powerful immunotherapy and targeted therapy regimen—prior to thrombectomy in patients with RCC and IVC involvement. This work addresses a critical gap in the literature, as combination therapy had not previously been reported for this high-risk population. With 5 citations in a short time, Dr. Kondo’s study has already begun to shape clinical decision-making for complex RCC cases, offering new hope for downstaging tumors and improving surgical outcomes. Her research bridges the gap between medical oncology and urologic surgery, highlighting a multidisciplinary approach to aggressive disease. Dr. Kondo’s contributions are vital for surgeons and oncologists seeking to expand treatment options for patients with advanced RCC, positioning her as an emerging leader in the field.
Research Focus
Key Achievements
Top Papers
- 1